Dian He a , c , Qizhu Wu b , Xiuying Chen a , Daidi Zhao a , Qiyong Gong b and Hongyu Zhou a , , a Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China b Department of Radiology, Huaxi MR Research Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China c Department of Neurology, Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou Province, China Accepted 27 May 2011.? Available online 1 July 2011. ? Abstract The objective of this study investigated cognitive impairments and their correlations with fractional anisotropy (FA) and mean diffusivity (MD) in patients with neuromyelitis optica (NMO) without visible lesions on conventional brain MRI during acute relapse.
Quantification of retinal neural loss in patients with neuromyelitis optica and multiple sclerosis with or without optic neuritis using optical coherence tomography Mario L.R. Monteiro 1, Danilo B
BACKGROUND: The role of different chemokine receptors in the pathogenesis of multiple sclerosis (MS) has been extensively investigated; however, little is known about the difference in the role of chemokine receptors between the pathogenesis of neuromyelitis optica (NMO) and MS. Therefore, we examined the expression of chemokine receptors on peripheral blood lymphocytes (PBL) in MS and NMO. METHODS: We used flow cytometry to analyse lymphocyte subsets in 12 patients with relapsing NMO, 24 with relapsing-remitting MS during relapse, 3 with NMO and 5 with MS during remission.
We evaluated 30 patients with clinically definite multiple sclerosis (MS) and 8 patients with neuromyelitis optica (NMO) to investigate correlations between Th1/Th2 balance, disease activity, effects of interferon (IFN)-beta treatment, and expressions of chemokine receptors CXCR3 and CCR4 on CD4+ and CD8+ T cells in peripheral blood. MS and NMO patients in the relapsing phase showed a significantly increased CD4+CXCR3+/CD4+CCR4+ ratio and CD8+CXCR3+/CD8+CCR4+ ratio compared with respective patients in the remission phase
Matrix metalloproteinase-9 (MMP-9) plays an important role in some neuroinflammatory diseases through the blood-brain barrier (BBB) disruption.
Background: Neuromyelitis optica (NMO) is characterized by severe optic neuritis and transverse myelitis. A disease-specific autoantibody against aquaporin (AQP) 4, mainly expressed in astrocytic foot processes, was found in the sera from patients with NMO.
Background: Acute transverse myelitis (ATM) in patients with no history of central nervous system (CNS) demyelinating disease may be idiopathic or herald the development of neuromyelitis optica spectrum disorder (NMOSD) or multiple sclerosis (MS). NMOSD may differ from MS in pathogenesis, prognosis and response to treatment, and radiological features at the first presentation of ATM that distinguish between NMOSD and MS would be desirable
Background: Neuromyelitis optica (NMO) is an aggressive devastating autoimmune disorder affecting predominantly optic nerves and the spinal cord. We are able to assess the serum antibodies against aquaporin 4 (anti-AQP4 Ab, also known as NMO-IgG), which are highly sensitive and specific for NMO.
OBJECTIVE: To explore the relationship between serum lipoproteins and clinical presentations of NMO patients. To investigate the differences of serum lipoprotein levels between NMO and MS patients. PATIENTS AND METHODS: Serum lipoprotein levels were measured in 56 NMO patients, 53 MS patients and 54 health subjects.
There are two distinct subtypes of multiple sclerosis (MS) in Asians: opticospinal (OSMS) and conventional (CMS). OSMS has similar features to neuromyelitis optica (NMO) and half of OSMS patients have the NMO-Immunoglobulin G (IgG)/ anti-aquaporin-4 (AQP4) antibody.
BACKGROUND: Antibodies to aquaporin-4 (AQP4) are found in a fraction of Japanese opticospinal multiple sclerosis (OSMS) patients. However, it remains unknown whether anti-AQP4 antibody-positive and negative OSMS patients possess an identical disease
OBJECTIVE: To evaluate the efficacy and safety of repeated rituximab treatment based on the assessment of peripheral circulating memory B cells over 24 months in patients with relapsing neuromyelitis optica (NMO). DESIGN: Prospective open-label study.